ADL 10-0101

DB05443ExperimentalSmall molecule

ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment of inflammatory pain,... Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic doses, it is expected to avoid central nervous system side effects.

Mechanism: Agonist at peripheral kappa opioid receptors
Curator reviewed
Primary indication: Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.Curator reviewed
Code names: ADL 10-0101

Resolves to

Targets

P41145OPRK1

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with ADL 10-0101, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account